Day: December 2, 2024

DALLAS, Dec. 02, 2024 (GLOBE NEWSWIRE) — P10, Inc. (NYSE: PX), (“P10” or the “Company”), a leading private markets solutions provider, today announced the appointment of Mike Goodwin as Chief Information Officer, effective December 2, 2024. Mr. Goodwin will lead the Company’s data, technology, and infrastructure function, providing strategic leadership across the P10 platform. “As Chief Information Officer, Mike Goodwin will add critical expertise to our deep, seasoned team,” said Luke Sarsfield, P10 Chairman and Chief Executive Officer. “Mike’s extensive experience in data strategy, cybersecurity, and technology strategy will be instrumental as we continue to enhance our operational and technological capabilities. We believe his leadership will strengthen our ability to serve clients and drive innovation across the organization.” In...

Transaction Creates Opportunity to Share in Potential Upside of Pharma Two B’s Late-Clinical Stage Candidate to Treat Parkinson’s Disease Hepion’s Board Unanimously Recommends Shareholders Approve the Merger Following Review of Strategic Alternatives – Including Challenges of Remaining a Stand-Alone Company EDISON, NJ, Dec. 02, 2024 (GLOBE NEWSWIRE) — Hepion Pharmaceuticals, Inc. (Nasdaq: HEPA) (“Hepion” or the “Company”), today sent an open letter to shareholders urging them to vote for Hepion’s proposed merger with Pharma Two B Ltd. (“Pharma Two B”) at the Company’s upcoming Special Meeting of Stockholders (the “Special Meeting”) on December 12, 2024. The full text of the letter is below: December 2, 2024 Dear Shareholders of Hepion Pharmaceuticals, We are writing to encourage your support for Hepion’s proposed merger with Pharma...

CAMBRIDGE, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) — CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases, today announced that management will present and be available for one-on-one meetings at the Piper Sandler 36th Annual Healthcare Conference to be held at the Lotte New York Palace Hotel in New York City December 3rd – 5th, 2024.Piper Sandler 36th Annual Healthcare Conference Presentations Date: December 5, 2024   Time: 1:00-1:25 PM ET   Webcast Link: Click Here   A live webcast of the presentation will be available via the Events section of the Company’s investor relations website...

SAN DIEGO, Dec. 02, 2024 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS), a technology company in Defense, National Security and Global Markets, is proud to announce its participation as a Gold Sponsor of the upcoming Reagan National Defense Forum (RNDF). This prestigious event, held at the Ronald Reagan Presidential Library in Simi Valley, California, brings together national security leaders, policymakers, industry executives, and military officials to discuss the pressing challenges and opportunities facing our nation’s defense. As a Gold Sponsor, Kratos is reinforcing its commitment to advancing innovative technologies that support the warfighter and address critical national security priorities. The company’s leadership will join the dialogue on key topics, including the modernization of defense...

DENVER, Dec. 02, 2024 (GLOBE NEWSWIRE) —  authID®  (Nasdaq: AUID) (“authID”), a leading provider of biometric identity verification and authentication solutions, today announced Berify, an authentication, consumer experience & signal harnessing organization, as a customer and OEM partner. Berify will secure its global user base with authID’s ProofTM and VerifiedTM solutions for onboarding and authenticating, and will OEM authID’s biometric solutions as a part of its platform to solve multiple enterprise use cases in the Asia Pacific market. Berify’s integrated platform combines blockchain, cybersecurity, consumer engagement and intuitive dashboards that allow its partner brands to create limitless product experiences, and social interactions for their consumers that generate valuable zero-party data for the client.. “authID...

BOSTON, Dec. 02, 2024 (GLOBE NEWSWIRE) — Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will present at the Piper Sandler 36th Annual Healthcare Conference taking place in New York City, NY December 3-5, 2024. Presentation detailsDate: Wednesday, December 4, 2024Time: 9:50-10:10 AM ESTWebcast Link: https://event.webcasts.com/ Virtual/Replay availability: The corporate presentation will be archived for 90 days on Compass’ Events page. About Compass TherapeuticsCompass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus...

Former executive at RingCentral, Five9 and Cisco, joins to lead product innovation and scale growth of Freshworks’ AI, CX and EX solutionsFreshworks Appoints Srinivasan Raghavan as Chief Product OfficerFormer executive at RingCentral, Five9 and Cisco, joins to lead product innovation and scale growth of Freshworks’ AI, CX and EX solutionsSAN MATEO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) — Freshworks Inc. (NASDAQ: FRSH) today announced Srinivasan Raghavan as its new Chief Product Officer (CPO) with over two decades of leadership experience in the enterprise SaaS industry. Srini will lead and scale the Freshworks’ product strategy and vision for its people-first AI service software used to deliver exceptional customer experiences (CX) and employee experiences (EX). He joins the Freshworks executive management team, reporting...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®) and Partner Therapeutics, Inc. (PTx), a private, fully-integrated biotechnology company with a focus in hematology and oncology, today announced they have entered into an agreement in which Merus has exclusively licensed to PTx the right to commercialize zenocutuzumab (Zeno) for the treatment of NRG1 fusion-positive (NRG1+) cancer in the United States (U.S.). “We are thrilled to work with the seasoned team at PTx to advance our mission to bring Zeno to patients with NRG1+ cancer,” said Shannon Campbell, Chief Commercial Officer of Merus. “We believe PTx is an ideal partner...